

特急

中国疾病预防

控制中心

病毒病预防控制所文件

中疾控病科技发〔2020〕1号

病毒病预防控制所关于加强新型冠状病毒感染的肺炎疫情防控期间有关科技成果管理的通知

各处室:

为贯彻落实习近平总书记重要讲话、重要指示精神，坚决打赢疫情防控阻击战，根据中国生物技术发展中心《关于进一步加强新冠肺炎科研应急攻关项目成果管理的通知》(附件1)、《中国疾病预防控制中心关于印发加强新型冠状病毒感染的肺炎应急响应期间有关科技管理规定的通知》(中疾控科技便函〔2020〕128号)(附件2)要求，进一步加强和规范我所新冠肺炎疫情防控期间有关科研成果管理，现将有关事项通知如下:

一、成果发布报备要求

(一) 新冠肺炎科研应急攻关项目在科研过程中发生的重要进展和重大成果，拟以文章形式发表，或通过媒体渠道公开发布的，填报《科研应急攻关项目成果发布报备表》(一式两份)报科技处。科技处协助办理上报中国生物技术发展中心审批手续。

(二) 中国生物技术发展中心批准发布后，媒体发布按照中国疾控中心的有关规定执行。

二、研究数据汇交和成果共享要求

根据中国生物技术发展中心通知要求，项目承担单位/参与单位应及时汇交项目实施过程中产生的涉及新冠肺炎的实验数据、临床病例、流行病学统计数据等，并按规定提供相关国家科学数据中心共享使用。

三、发表论文要求

在疫情防控期间，发表与新冠肺炎相关的论文应遵照中国科协、教育部、科技部、卫生计生委、中科院、工程院、自然科学基金会《发表学术论文“五不准”》(科协发组字〔2015〕98号)(附件3)精神，加强科学道德和学风建设，抵制学术不端行为。

凡署名“中国疾病预防控制中心病毒病预防控制所”的论文，均须经所科技处上报中心办理审批手续，待上级部门批准后方可正式发表。

四、联系方式

联系人： 赵秀军

联系电话: [REDACTED], [REDACTED]

邮箱: [REDACTED]

- 附件: 1. 中国生物技术发展中心《关于进一步加强新冠肺炎科研应急攻关项目成果管理的通知》
2. 中国疾病预防控制中心关于印发加强新型冠状病毒感染的肺炎应急响应期间有关科技管理规定的通知 (中疾控科技便函〔2020〕128号)
3. 中国科协、教育部、科技部、卫生计生委、中科院、工程院、自然科学基金会《发表学术论文“五不准”》(科协发组字〔2015〕98号)

中国疾病预防控制中心
病毒病预防控制所
2020年2月24日

Urgent

Chinese Center for Disease Control and Prevention Viral Disease Control and Prevention Institute Document

China CDC Viral Disease Science and Technology Development [2020] No. 1

Notice of the Institute of Viral Disease Prevention and Control on Strengthening Management of Scientific and Technological Achievements During the Prevention and Control Period of the Novel Coronavirus Pneumonia Epidemic

To all offices:

In order to thoroughly carry out the spirit of the important speeches and instructions of General Secretary Xi Jinping, win the fight against the epidemic, and in accordance with the requirements of the China Biotechnology Development Center's "Notice on Further Strengthening the Management of Novel Coronavirus Pneumonia Scientific Research Projects" (Annex 1) and the "Notice of the Chinese Center for Disease Control and Prevention on the Issuance of Relevant Regulations on Science and Technology Management During the Emergency Response Period Against the Novel Coronavirus Pneumonia" (China CDC Science and Technology Memo [2020] No. 128) (Annex 2), we will further strengthen and standardize the management of scientific research results in our institute during the prevention and control period of the novel coronavirus pneumonia epidemic. We now notify you of the relevant matters below:

I. Reporting requirements before publication

(1) For important progress and results discovered during the research process under the novel coronavirus pneumonia emergency research project, if

you intend to publish papers or release it publicly through the media, fill in the "Report Form for Scientific Research Emergency Research Project Results Publication" (and duplicate) and report it to the Office of Science and Technology. The Office of Science and Technology will assist with the procedures for reporting it up to the China Biotechnology Development Center for approval.

(2) After the China Biotechnology Development Center approves publication, media publication will follow the relevant regulations of the Chinese Center for Disease Control and Prevention.

II. Requirements for transferring data and sharing results

According to the requirements of the China Biotechnology Development Center notice, the undertaker/participant of the project should submit experimental data, clinical cases, epidemiological statistics, etc. generated during research related to the novel coronavirus pneumonia in a timely manner, and also provide it to the relevant national scientific data centers for shared use in accordance with regulations.

III. Requirements for Publication

During the epidemic prevention and control period, the publication of papers related to the novel coronavirus pneumonia should be in accordance with the spirit of the notice on "The 'five prohibitions' on the publication of academic papers" (Chinese Association of Science and Technology [2015] No. 98) (Annex 3) by the Chinese Association of Science and Technology, the Ministry of Education, the Ministry of Science and Technology, the Health and Family Planning Commission, the Chinese Academy of Sciences, the Academy of Engineering, and the Natural Science Foundation, in order to strengthen scientific ethics and academic spirit and resist academic misconduct.

All papers under the name of "The Institute of Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention" must be reported by the Science and Technology Office of the Institute to the Center for approval procedures, and they can only be formally published after approval by the higher authorities.

IV: Contact information

Contact: Zhao Xiujun

Phone: [REDACTED], [REDACTED]

Email: [REDACTED]

- Attachment: 1. The China Biotechnology Development Center
“Notice on Further Strengthening the Management of Novel
Coronavirus Pneumonia Scientific Research Projects”
2. Notice of the Chinese Center for Disease Control and Prevention
on the Issuance of Relevant Regulations on Science and Technology
Management During the Emergency Response Period Against the
Novel Coronavirus Pneumonia (China CDC Science and Technology
Memo [2020] No. 128)
3. The Chinese Association of Science and Technology, the Ministry of
Education, the Ministry of Science and Technology, the Health and
Family Planning Commission, the Chinese Academy of Sciences, the
Academy of Engineering, and the Natural Science Foundation’s “The
‘five prohibitions’ on the publication of academic papers” (Chinese
Association of Science and Technology [2015] No. 98)

Institute for Viral Disease Control and Prevention
Chinese Center for Disease Control and Prevention
February 24, 2020